MiMedx Group, Inc (NASDAQ:MDXG) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $8.50.

A number of equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Citizens Jmp dropped their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Weiss Ratings downgraded shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Finally, Craig Hallum decreased their target price on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th.

MiMedx Group Price Performance

Shares of MDXG stock opened at $4.17 on Thursday. The stock has a 50 day moving average of $3.84 and a two-hundred day moving average of $4.33. The company has a current ratio of 5.39, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.99. The company has a market capitalization of $621.12 million, a P/E ratio of 20.85 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. The company had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%. As a group, equities analysts expect that MiMedx Group will post -0.09 EPS for the current year.

Institutional Investors Weigh In On MiMedx Group

Large investors have recently modified their holdings of the stock. SkyView Investment Advisors LLC raised its stake in MiMedx Group by 3.6% during the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after acquiring an additional 3,032 shares in the last quarter. Rafferty Asset Management LLC lifted its holdings in shares of MiMedx Group by 4.6% during the fourth quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after acquiring an additional 3,064 shares during the period. Aviva PLC boosted its stake in shares of MiMedx Group by 4.7% in the 4th quarter. Aviva PLC now owns 71,234 shares of the company’s stock valued at $482,000 after purchasing an additional 3,211 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of MiMedx Group by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after purchasing an additional 4,049 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of MiMedx Group by 42.6% in the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.